Sherpa Venture Capital
71
46M
54
11.83
10
0.24
- Stages of investment
- Areas of investment
Summary
In 2018 was created Sherpa Venture Capital, which is appeared as VC. The venture was found in Asia in China. The leading representative office of defined VC is situated in the Beijing.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular fund investment industries, there are Medical Device, Clinical Trials. Among the most popular portfolio startups of the fund, we may highlight EpimAb Biotherapeutics, Singleron Biotechnologies, Immunochina. The fund has exact preference in a number of founders of portfolio startups.
The fund is constantly included in 7-12 investment rounds annually. Considering the real fund results, this VC is 60 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2019.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Sherpa Venture Capital, startups are often financed by Trend Investment Group, Thiel Capital, ShengJing360. The meaningful sponsors for the fund in investment in the same round are Legend Capital, Hillhouse Capital Group, WuXi AppTec.
We also calculated 2 valuable employees in our database.
Investments analytics
Analytics
- Total investments
- 71
- Lead investments
- 10
- Rounds per year
- 11.83
- Follow on index
- 0.24
- Investments by industry
- Biotechnology (45)
- Health Care (28)
- Medical (17)
- Therapeutics (13)
- Pharmaceutical (11) Show 29 more
- Investments by region
-
- China (58)
- United States (10)
- France (1)
- Kenya (1)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Avg. valuation at time of investment
- 33M
- Group Appearance index
- 0.96
- Avg. company exit year
- 5
- Strategy success index
- 0.20
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Huihe Healthcare | 07 Dec 2022 | Health Care, Medical Device, Medical | Late Stage Venture | Shanghai, Shanghai, China | |
| Vazyme Biotech | 05 Dec 2020 | Biotechnology, Life Science | Late Stage Venture | 85M | Jiangsu, Xuanwu District, China |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.